- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07695389
Efficacy of a Novel Cellular, Acellular, Matrix-like Product (CAMP) Plus Standard of Care Versus Standard of Care Alone in the Management of Post-Mohs Micrographic Surgery Defects. (BIOMOHS)
A Multicenter, Prospective, Randomized Controlled Clinical Trial Assessing the Efficacy of a Novel Cellular, Acellular, Matrix-like Product (CAMP) Plus Standard of Care Versus Standard of Care Alone in the Management of Post-Mohs Micrographic Surgery Defects.
A multicenter, prospective, randomized controlled clinical trial assessing the efficacy of a novel cellular, acellular, matrix-like product (CAMP) plus standard of care versus standard of care alone in the management of post-mohs micrographic surgery defects.
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
This study will utilize a Prospective, Multicenter, Randomized Controlled Clinical Trial design.
Subjects will be adult patients undergoing Mohs micrographic surgery with resulting post-excisional defects suitable for healing by secondary intention or management with a topical matrix-like product.
Subjects will be randomized to receive:
- CAMP plus Standard of Care (SOC), or
- Control Dressing plus SOC. Randomization will occur after confirmation of final Mohs stage and measurement of the post-excisional defect.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Bennett Sarver
- Numéro de téléphone: 1-833-865-6300
- E-mail: info@serenagroups.com
Lieux d'étude
-
-
Oklahoma
-
Tulsa, Oklahoma, États-Unis, 74132
- Recrutement
- Southside Dermatology Mohs and Skin Surgery
-
Contact:
- Ana Montalva
- Numéro de téléphone: (918) 760-0700
- E-mail: amontalva@dermatologyok.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
The potential subject must be at least 18 years of age or older.
-
The potential subject must have undergone Mohs micrographic surgery for a cutaneous malignancy (e.g., basal cell carcinoma, or squamous cell carcinoma).
-
The potential subject must have a post-Mohs surgical defect that is suitable for treatment with a CAMP product or healing by secondary intention.
-
The surgical site has received standard Mohs excision and hemostasis with no requirement for immediate flap or graft reconstruction as determined by the treating surgeon.
-
If the surgical defect is on the lower extremity, the limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:
- Ankle-Brachial Index (ABI) between 0.7 and ≤ 1.3;
- Toe-Brachial Index (TBI) ≥ 0.6;
- Transcutaneous Oxygen Measurement (TCOM) ≥ 40 mmHg;
- Pulse Volume Recording (PVR): biphasic.
-
If the subject has multiple Mohs defects, they must be separated by at least 2 cm. The largest defect satisfying the inclusion and exclusion criteria will be designated as the target wound.
-
The potential subject must agree to attend the weekly study visits required by the protocol.
-
The potential subject must be willing and able to participate in the informed consent process.
Exclusion Criteria:
-
The potential subject is known to have a life expectancy of < 6 months.
-
The potential subject's target wound is not secondary to a Mohs excision.
-
The target wound is infected or there is cellulitis in the surrounding skin.
-
The target wound:
- Exposes tendon, bone, or joint space, and/or
- Requires immediate complex flap or graft reconstruction in the judgment of the surgeon.
-
The potential subject has participated in a clinical trial involving treatment with an investigational product within the previous 30 days.
-
The potential subject has glycated hemoglobin (HbA1c) greater than 10% within 3 months of the initial screening visit.
-
The potential subject, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Control Dressing + Standard of Care
Standard of care will be cleaning, debridement, ulcer moisture balance, control dressing and offloading. |
Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 6 weeks, whichever occurs first. |
|
Autre: CAMP + Standard of Care
Membrane Wrap-Lite is a human amniotic membrane tissue allograft derived from human placental tissue. |
Participants will receive weekly applications of Membrane Wrap-Lite and Standard of Care until ulcer closure, or a maximum of 6 weeks, whichever occurs first. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Complete Wound Closure
Délai: 1-6 Weeks
|
The percentage of target wounds achieving complete wound closure in 6 weeks. |
1-6 Weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to Closure
Délai: 1-6 Weeks
|
Time to closure for the target wound. |
1-6 Weeks
|
|
Percentage Area Reduction
Délai: 1-6 weeks
|
Percentage wound area reduction from TV-1 to TV-6 measured weekly with digital photographic planimetry using imaging device and physical examination. |
1-6 weeks
|
|
Procedure-Related Adverse Events
Délai: 1-6 Weeks
|
The number of product- or procedure-related adverse events. |
1-6 Weeks
|
|
Wound Volume Reduction
Délai: 1-6 Weeks
|
Percentage wound volume reduction from TV-1 to TV-6 measured weekly with digital photographic planimetry using imaging device and physical examination. |
1-6 Weeks
|
|
Product or Procedure Adverse Events
Délai: 1-6 Weeks
|
The number of product- or procedure-related adverse events. |
1-6 Weeks
|
|
Numeric Pain Scale
Délai: 1-6 weeks
|
Change in pain at the target wound site assessed using a numeric pain scale. 0 being no pain and 10 being the worst pain imaginable. |
1-6 weeks
|
|
Economic Outcomes
Délai: 1-6 Weeks
|
Health economic outcomes, including direct and indirect cost of care. |
1-6 Weeks
|
|
Quality of Life
Délai: 1- 6 Weeks
|
Change in quality of life, using the Wound Quality of Life Questionnaire, with items scored 0-4, where higher scores indicate worse quality of life. |
1- 6 Weeks
|
|
Scare and Cosmetic Outcomes
Délai: 12 Months
|
Scar and cosmetic outcomes at 12 months using the Patient and Observer Scar Assessment Scale (POSAS). 0 being normal and 10 being very different. |
12 Months
|
|
Time to Complete Granulation Tissue
Délai: 1-6 Weeks
|
Time to complete granulation tissue confirmed by independent assessment. |
1-6 Weeks
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Perfusion
Délai: 1-6 Weeks
|
Changes in local perfusion at the surgical site over the 6-week treatment period, assessed via near-infrared spectroscopy. |
1-6 Weeks
|
|
Rate of Recurrence
Délai: 12 Months
|
The rate of recurrence within 12 months of closure when applicable. |
12 Months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Thomas Serena, MD, Serena Group, Inc.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- To be determined
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .